New Aspects of Melasma/Novi aspekti melazme

1. Rivas S, Pandya AG. Treatment of melasma with topical agents, peels and lasers: an evidence-based review. Am J Clin Dermatol. 2013 Oct;14(5):359-76.10.1007/s40257-013-0038-423881551Search in Google Scholar

2. Ho SG, Chan HH. The Asian dermatologic patient: review of common pigmentary disorders and cutaneous diseases. Am J Clin Dermatol. 2009;10(3):153-68.10.2165/00128071-200910030-0000219354330Search in Google Scholar

3. Tamega Ade A, Miot LD, Bonfietti C, Gige TC, Marques ME, Miot HA. Clinical patterns and epidemiological characteristics of facial melasma in Brazilian women. J Eur Acad Dermatol Venereol. 2013; 27(2):151-6.10.1111/j.1468-3083.2011.04430.x22212073Search in Google Scholar

4. Hexsel D, Lacerda DA, Cavalcante AS, Machado Filho CA, Kalil CL, Ayres EL, et al. Epidemiology of melasma in Brazilian patients: a multicenter study. Int J Dermatol. 2014;53(4):440-4.10.1111/j.1365-4632.2012.05748.x23967822Search in Google Scholar

5. Wu IB, Lambert C, Lotti TM, Hercogova J, Sintim-Damoa A, Schwartz RA. Melasma. G Ital Dermatol Venereol. 2012 Aug;147(4):413-8.Search in Google Scholar

6. Kim NH, Lee CH, Lee AY. H19 RNA downregulation stimulated melanogenesis in melasma. Pigment Cell Melanoma Res. 2010 Feb;23(1):84-92.10.1111/j.1755-148X.2009.00659.x19968822Search in Google Scholar

7. Perez-Bernal A, Munoz-Perez MA, Camacho F. Management of facial hyperpigmentation. Am J Clin Dermatol. 2000;1(5):261-810.2165/00128071-200001050-0000111702317Search in Google Scholar

8. Kim NH, Cheong KA, Lee TR, Lee AY. PDZK1 upregulation in estrogen-related hyperpigmentation in melasma. J Invest Dermatol. 2012 Nov;132(11):2622-31.10.1038/jid.2012.17522696060Search in Google Scholar

9. Lieberman R, Moy L. Estrogen receptor expression in melasma: results from facial skin of affected patients. J Drugs Dermatol. 2008 May;7(5):463-5.Search in Google Scholar

10. Perez M, Sanchez JL, Aguilo F. Endocrinologic profile of patients with idiopathic melasma. J Invest Dermatol. 1983;81(6):543-5.10.1111/1523-1747.ep125228966644096Search in Google Scholar

11. Sawhney M, Anand R. Chronic pelvic inflammatory disease and melasma in women. Indian J Dermatol Venereol Leprol. 2003;69(3):251-2.Search in Google Scholar

12. Ortonne JP, Arellano I, Berneburg M, Cestari T, Chan H, Grimes P, et al. A global survey of the role of ultraviolet radiation and hormonal influences in the development of melasma. J Eur Acad Dermatol Venereol. 2009 Nov;23(11):1254-62.10.1111/j.1468-3083.2009.03295.x19486232Search in Google Scholar

13. Bak H, Lee HJ, Chang SE, Choi JH, Kim MN, Kim BJ. Increased expression of nerve growth factor receptor and neural endopeptidase in the lesional skin of melasma. Dermatol Surg. 2009 Aug;35(8):1244-50.10.1111/j.1524-4725.2009.01219.x19438666Search in Google Scholar

14. Kim EJ, Park HY, Yaar M, Gilchrest BA. Modulation of vascular endothelial growth factor receptors in melanocytes. Exp Dermatol. 2005;14(8):625-33.10.1111/j.0906-6705.2005.00345.xSearch in Google Scholar

15. Kim EH, Kim YC, Lee ES, Kang HY. The vascular characteristics of melasma. J Dermatol Sci. 2007;46(2):111-6.10.1016/j.jdermsci.2007.01.009Search in Google Scholar

16. Lee JH, Park JG, Lim SH, Kim JY, Ahn KY, Kim My, et al. Localized intradermal microinjection of tranexamic acid for treatment of melasma in Asian patients: a preliminary clinical trial. Dermatol Surg. 2006;32(5):626-33.10.1097/00042728-200605000-00004Search in Google Scholar

17. Grimes PE, Yamada N, Bhawan J. Light microscopic, immunohistochemical, and ultrastructural alterations in patients with melasma. Am J Dermatopathol. 2005;27(2):96-101.10.1097/01.dad.0000154419.18653.2eSearch in Google Scholar

18. Katsambas A, Antoniou C. Melasma: classification and treatment. J Eur Acad Dermatol Venereol. 1995;4(3):217-23.10.1111/j.1468-3083.1995.tb00341.xSearch in Google Scholar

19. Gupta LK, Singhi MK. Wood’s lamp. Indian J Dermatol Venereol Leprol. 2004;70(2):131-5 .Search in Google Scholar

20. Sanchez NP, Pathak MA, Sato S, Fitzpatrick TB, Sanchez JL, Mihm Mc Jr. Melasma: a clinical, light microscopic, ultrastructural, and immunofluorescence study. J Am Acad Dermatol. 1981:4(6):698-710.10.1016/S0190-9622(81)70071-9Search in Google Scholar

21. Sheth VM, Pandya AG. Melasma: a comprehensive update: part I. J Am Acad Dermatol. 2011 Oct;65(4):689-97.10.1016/j.jaad.2010.12.04621920241Search in Google Scholar

22. Kimbrough-Green CK, Griffiths CE, Finkel LJ, Hamilton TA, Bulengo-Ransby SM, Ellis CN, et al . Topical retinoic acid (tretinoin) for melasma in black patients. A vehicle-controlled clinical trial. Arch Dermatol. 1994;130(6):727-33.10.1001/archderm.1994.01690060057005Search in Google Scholar

23. Pawaskar MD, Parikh P, Markowski T, McMichael AJ, Feldman SR, Balkrishnan R. Melasma and its impact on health-related quality of life in Hispanic women. J Dermatolog Treat. 2007;18(1):5-9.10.1080/0954663060102877817365259Search in Google Scholar

24. Cestari TF, Hexsel D, Viegas ML, Azulay L, Hassun K, Almeida Ar, et al. Validation of a melasma quality of life questionnaire for Brazilian Portuguese language: the MelasQoL-BP study and improvement of QoL of melasma patients after triple combination therapy. Br J Dermatol. 2006 Dec;156 Suppl 1:13-20.10.1111/j.1365-2133.2006.07591.x17176300Search in Google Scholar

25. Prignano F, Ortonne JP, Buggiani G, Lotti T. Therapeutical approaches in melasma. Dermatol Clin. 2007 Jul;25(3):337-42.10.1016/j.det.2007.04.006Search in Google Scholar

26. Smit N, Vicanova J, Pavel S. The hunt for natural skin whitening agents. Int J Mol Sci. 2009 Dec 10;10(12):5326-49. 10.3390/ijms10125326Search in Google Scholar

27. Katsambas AD, Stratigos AJ. Depigmenting and bleaching agents: coping with hyperpigmentation. Clin Dermatol. 2001 Jul-Aug;19(4):483-8.10.1016/S0738-081X(01)00182-1Search in Google Scholar

28. Solano F, Briganti S, Picardo M, Ghanem G. Hypopigmenting agents: an updated review on biological, chemical and clinical aspects. Pigment Cell Res. 2006 Dec;19(6):550-71.10.1111/j.1600-0749.2006.00334.x17083484Search in Google Scholar

29. Twenty-fourth directive 2000/6/EG Publication nr L 056, European Union; 2000.Search in Google Scholar

30. Westerhof W, Kooyers TJ. Hydroquinone and its analogues in dermatology - a potential health risk. J Cosmet Dermatol. 2005 Jun;4(2):55-9.10.1111/j.1473-2165.2005.40202.x17166200Search in Google Scholar

31. Enguita FJ, Leitao AL. Hydroquinone: environmental pollution, toxicity, and microbial answers. Biomed Res Int. 2013;2013:542168.Search in Google Scholar

32. Gillner M, Moore GS, Cederberg H. International Programme on Chemical Safety Panel of Experts. Environmental Health Criteria 157: Hydroquinone. Available from: http://www. inchem.org/documents/ehc/ehc/ehc157.htmSearch in Google Scholar

33. U.S. Food & Drug Administration, Department of Health and Human Services. Nomination Profile: Hydroquinone [CAS 123-31-9]. Supporting Information for Toxicological Evaluation by the National Toxicology Program 21 May 2009. Available from: http://ntp.niehs.nih.gov/ntp/noms/support_ docs/hydroquinone_may2009.pdfSearch in Google Scholar

34. Katsambas AD, Stratigos AJ, Lotti TM. Melasma. In: Katsambas AD, Lotti TM, editors. European handbook of dermatological treatments. 2nd ed. Berlin: Springer; 2003. p. 336-41.10.1007/978-3-662-07131-1_59Search in Google Scholar

35. Farshi S. Comparative study of therapeutic effects of 20% azelaic acid and hydroquinone 4% cream in the treatment of melasma. J Cosmet Dermatol. 2011 Dec;10(4):282-7.10.1111/j.1473-2165.2011.00580.x22151936Search in Google Scholar

36. Monteiro RC, Kishore BN, Bhat RM, Sukumar D, Martis J, Ganesh HK. A Comparative study of the efficacy of 4% hydroquinone vs 0.75% Kojic acid cream in the treatment of facial melasma. Indian J Dermatol. 2013 Mar;58(2):157.10.4103/0019-5154.108070365722723716817Search in Google Scholar

37. Deo KS, Dash KN, Sharma YK, Virmani NC, Oberai C. Kojic acid vis-a-vis its combinations with hydroquinone and betamethasone valerate in melasma: a randomized, single blind, comparative study of efficacy and safety. Indian J Dermatol. 2013 Jul;58(4):281-5.10.4103/0019-5154.113940372687423918998Search in Google Scholar

38. Taylor MB, Yanaki JS, Draper DO, Shurtz JC, Coglianese M. Successful short-term and long-term treatment of melasma and postinflammatory hyperpigmentation using vitamin C with a full-face iontophoresis mask and a mandelic/malic acid skin care regimen. J Drugs Dermatol. 2013 Jan;12(1):45-50.Search in Google Scholar

39. Ortonne JP. Retinoid therapy of pigmentary disorders. Dermatol Ther. 2006 Sep-Oct;19(5):280-810.1111/j.1529-8019.2006.00085.x17014483Search in Google Scholar

40. Gold M, Rendon M, Dibernardo B, Bruce S, Lucas-Anthony C, Watson J. Open-label treatment of moderate or marked melasma with a 4% hydroquinone skin care system plus 0.05% tretinoin cream. J Clin Aesthet Dermatol. 2013 Nov;6(11):32-8.Search in Google Scholar

41. Dogra S, Kanwar AJ, Parsad D. Adapalene in the treatment of melasma: a preliminary report. J Dermatol. 2002 Aug;29(8):539-40.10.1111/j.1346-8138.2002.tb00324.x12227492Search in Google Scholar

42. Faghihi G, Shahingohar A, Siadat AH. Comparison between 1% tretinoin peeling versus 70% glycolic acid peeling in the treatment of female patients with melasma. J Drugs Dermatol. 2011 Dec;10(12):1439-42.Search in Google Scholar

43. Brazzini B, Hautmann G, Ghersetich I, Hercogova J, Lotti T. Laser tissue interaction in epidermal pigmented lesions. J Eur Acad Dermatol Venereol. 2001 Sep;15(5):388-91.10.1046/j.0926-9959.2001.00313.x11763375Search in Google Scholar

44. Lee DB, Suh HS, Choi YS. A comparative study of lowfluence 1064-nm Q-switched Nd:YAG laser with or without chemical peeling using Jessner’s solution in melasma patients. J Dermatolog Treat. 2014 Dec;25(6):523-8.10.3109/09546634.2013.84826124289244Search in Google Scholar

45. Lee HI, Lim YY, Kim BJ, Kim MN, Min HJ, Hwang JH, et al. Clinicopathologic efficacy of copper bromide plus/yellow laser (578 nm with 511 nm) for treatment of melasma in Asian patients. Dermatol Surg. 2010 Jun;36(6):885-93.10.1111/j.1524-4725.2010.01564.x20482724Search in Google Scholar

46. Zaleski L, Fabi S, Goldman MP. Treatment of melasma and the use of intense pulsed light: a review. J Drugs Dermatol. 2012 Nov;11(11):1316-20.Search in Google Scholar

47. Figueiredo Souza L, Trancoso Souza S. Single-session intense pulsed light combined with stable fixed-dose triple combination topical therapy for the treatment of refractory melasma. Dermatol Ther. 2012 Sep-Oct;25(5):477-80.10.1111/j.1529-8019.2012.01530.x23046029Search in Google Scholar

48. Chung JY, Choi M, Lee JH, Cho S, Lee JH. Pulse in pulse intense pulsed light for melasma treatment: a pilot study. Dermatol Surg. 2014 Feb;40(2):162-8.10.1111/dsu.1241424433388Search in Google Scholar

49. Rendon M, Berneburg M, Arellano I, Picardo M. Treatment of melasma. J Am Acad Dermatol. 2006 May;54(5 Suppl 2):S272-81.10.1016/j.jaad.2005.12.03916631968Search in Google Scholar

50. Draelos ZD. Skin lightening preparations and the hydroquinone controversy. Dermatol Ther. 2007 Sep-Oct;20(5):308-13.10.1111/j.1529-8019.2007.00144.x18045355Search in Google Scholar

51. Yousefi A, Khani Khoozani Z, Zakerzadeh Forooshani S, Omrani N, Moini AM, Eskandari Y. Is topical zinc effective in the treatment of melasma? A double-blind randomized comparative study. Dermatol Surg. 2014 Jan;40(1):33-7.10.1111/dsu.1229624237751Search in Google Scholar

52. Zhu W, Gao J. The use of botanical extracts as topical skinlightening agents for the improvement of skin pigmentation disorders. J Investig Dermatol Symp Proc. 2008 Apr;13(1):20-4. 10.1038/jidsymp.2008.818369335Search in Google Scholar